Most lung nodules are benign and never need to be removed. The right approach depends entirely on what the nodule is: an old scar from a past infection, a small focus of inflammation, or, less commonly, an early-stage cancer. For nodules that do require treatment, options range from antifungal medications to minimally invasive surgery to focused radiation, each matched to the underlying cause and the patient’s overall health. The challenge, and the source of much anxiety, is figuring out which category your nodule falls into before deciding on a course of action.
Why Most Nodules Are Watched, Not Treated
A lung nodule is a small spot, usually less than 3 centimeters across, that shows up on a chest CT scan. They are strikingly common. Many appear incidentally when imaging is done for an unrelated reason, like a cardiac workup or an abdominal scan. The vast majority turn out to be harmless: granulomas from old infections, small lymph nodes, or tiny areas of scarring. Because of this, the default response for most small, incidentally found nodules is not treatment but surveillance with follow-up CT scans over time.
The Fleischner Society, whose guidelines are widely used by radiologists and pulmonologists, updated its recommendations in 2017 to raise the minimum size threshold for routine follow-up, meaning that the smallest nodules (generally under 6 mm in low-risk patients) no longer need serial imaging at all.1PubMed. Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017 The updated guidelines also shifted from fixed follow-up timelines to recommended ranges, giving doctors and patients more flexibility to account for individual risk factors.2PubMed. Updated Fleischner Society Guidelines for Managing Incidental Pulmonary Nodules: Common Questions and Challenging Scenarios The key idea: a nodule that stays the same size over two or more years of surveillance is overwhelmingly likely to be benign, and no further action is needed.
How Doctors Decide Which Nodules Are Concerning
When a nodule is large enough to warrant attention, physicians use a mix of clinical history and imaging features to estimate the likelihood of malignancy. Several validated prediction models exist for this purpose. The Mayo Clinic model, for instance, weighs patient age, nodule size, smoking history, prior cancer history, upper-lobe location, and spiculated (spiky) edges. The Brock University model adds factors like family history of cancer and emphysema. A third tool, the Herder model, incorporates PET scan uptake data in addition to clinical and CT features.3PubMed Central. Comparison of Brock University, Mayo Clinic and Herder models for pretest probability of cancer in solid pulmonary nodules In validation studies, the Mayo and Brock models have performed similarly, with strong accuracy in distinguishing benign from malignant nodules.4PubMed. Risk of malignancy in pulmonary nodules: A validation study of four prediction models
These models matter because they shape what happens next. A nodule with a low estimated probability of cancer goes into surveillance. One with intermediate risk might be sent for a PET scan or a biopsy. A high-risk nodule often goes straight to tissue sampling or surgical removal. Geography plays a role too: in regions where fungal infections like coccidioidomycosis are common, nodules from those infections can mimic cancer on imaging. Radiographic clues like cavitation inside the nodule and the presence of satellite nodules around it can help distinguish fungal nodules from malignant ones.5PubMed Central. Differentiating Lung Nodules Due to Coccidioides from Those Due to Lung Cancer Based on Radiographic Appearance
Getting a Definitive Diagnosis Through Biopsy
When imaging alone cannot settle the question, a tissue biopsy is the next step. The two main approaches are CT-guided transthoracic needle biopsy, where a needle is inserted through the chest wall under CT guidance, and bronchoscopy, where a flexible scope is threaded through the airways. Both have high diagnostic accuracy, but they come with different risk profiles.
Robotic-assisted bronchoscopy has emerged as a newer option that can reach nodules deep in the lung with greater precision than conventional bronchoscopy. In one comparative study, robotic-assisted bronchoscopy and CT-guided transthoracic biopsy had similar overall diagnostic yields (about 88%), but the complication rate was significantly lower with the robotic approach (roughly 4% versus 17%).6PubMed. Robotic-assisted bronchoscopy versus CT-guided transthoracic biopsy for diagnosis of pulmonary nodules The main complication with transthoracic biopsy is pneumothorax, a partial lung collapse caused by air leaking through the puncture site. A more recent study comparing a shape-sensing robotic bronchoscopy system with CT-guided biopsy found no complications in the robotic group and a handful of pneumothoraces requiring chest tubes in the CT-guided group.7CHEST Pulmonary. CT Scan-Guided Biopsy vs Shape-Sensing Robotic-Assisted Bronchoscopy: Molecular Analysis, Diagnostic Yield, and Clinical Implications The robotic approach also allows doctors to biopsy more than one nodule in the same session and to stage the mediastinal lymph nodes at the same time, which can change the treatment plan substantially.
Treating Nodules Caused by Infection
Not every nodule that needs treatment is cancer. Fungal infections are one of the most common benign causes of lung nodules, particularly in certain parts of the world. Histoplasmosis, caused by a soil fungus found in river valleys, frequently produces pulmonary nodules that can persist for months or years. Chronic pulmonary histoplasmosis can even masquerade as tuberculosis or cancer on imaging.8International Journal of Surgery Case Reports. Chronic pulmonary histoplasmosis masquerading as tuberculoma: A case report and literature review
For people with healthy immune systems who develop mild acute histoplasmosis, antifungal therapy with itraconazole is the standard treatment. Severe or disseminated disease calls for a more aggressive initial approach with liposomal amphotericin B, with a step-down to itraconazole once the patient improves.9PubMed Central. Pulmonary Histoplasmosis: A Clinical Update Chronic cases typically require at least a year of itraconazole, and some clinicians extend treatment to two years to reduce the chance of relapse.10Open Forum Infectious Diseases. Chronic Pulmonary Histoplasmosis—A Scoping Literature Review Coccidioidomycosis, another fungal infection common in the southwestern United States, can also form persistent nodules that may or may not require treatment depending on symptoms and immune status. The point is that for infection-related nodules, antifungal or antimicrobial therapy can resolve the nodule without any surgical intervention.
Treating Nodules Linked to Autoimmune Disease
Rheumatoid arthritis is an underappreciated cause of pulmonary nodules. These rheumatoid nodules can appear in the lungs as part of the systemic disease, and a particularly tricky scenario occurs when methotrexate, one of the most common rheumatoid arthritis drugs, paradoxically triggers a burst of new or enlarged lung nodules known as accelerated rheumatoid nodules. The typical first step is to stop the offending medication and start corticosteroids. Newer targeted therapies, including Janus kinase inhibitors like baricitinib, have shown promise in treating these nodules.11PubMed. Rheumatoid arthritis with pulmonary accelerated rheumatoid nodules treated by baricitinib: a case-based review This is a situation where the lung nodule is really a symptom of a broader condition, and treating the underlying disease is the path to resolution.
Surgical Removal of Lung Nodules
When a nodule is confirmed malignant or strongly suspected of being cancer, surgical removal is often the most definitive treatment. The good news is that lung surgery has moved far beyond the large chest incisions of decades past. Video-assisted thoracoscopic surgery (VATS) allows surgeons to remove nodules through small incisions using a camera and specialized instruments. For peripheral nodules, a wedge resection removes just the nodule and a margin of surrounding tissue, preserving as much healthy lung as possible.
One study found that VATS wedge excision of small pulmonary nodules was successful in avoiding a full thoracotomy in over 80% of patients, with minimal complications.12PubMed. Feasibility and value of video-assisted thoracoscopic surgery wedge excision of small pulmonary nodules in patients with malignancy Surgeons have continued refining the approach: uniportal VATS uses a single small incision rather than several, and some centers now perform the procedure without general anesthesia using regional nerve blocks, further reducing recovery time and complications.13PubMed. Tubeless Uniportal Thoracoscopic Wedge Resection for Peripheral Lung Nodules Non-intubated approaches, where the patient breathes on their own during surgery, have been adopted at specialized centers for suitable patients.14Frontiers in Surgery. Non-intubated Thoracic Surgery: Wedge Resections for Peripheral Pulmonary Nodules
For nodules that appear to be early-stage lung adenocarcinoma presenting as pure ground-glass opacities, limited resection (sublobar rather than a full lobectomy) has been shown to be sufficient for cure. These slow-growing lesions have an excellent prognosis, and there appears to be no additional benefit from removing mediastinal lymph nodes in pure ground-glass cases.15European Journal of Cardio-Thoracic Surgery. Surgical management of pulmonary adenocarcinoma presenting as a pure ground-glass nodule Combined high-resolution CT and PET/CT imaging helps surgeons and oncologists determine preoperatively whether a ground-glass nodule harbors invasive cancer, which affects how aggressive the surgery needs to be.16PubMed. Lung Adenocarcinoma Manifesting as Ground-Glass Opacity Nodules 3 cm or Smaller: Evaluation With Combined High-Resolution CT and PET/CT Modality
Radiation as an Alternative to Surgery
Not everyone is a good candidate for surgery. Older patients, those with severe lung disease, or people with other major health conditions may face unacceptable surgical risks. Stereotactic body radiotherapy (SBRT) delivers high doses of precisely focused radiation to a lung nodule in just a few sessions, typically three to five, while largely sparing the surrounding tissue. It has become a standard option for early-stage lung cancers in patients who cannot undergo surgery.
SBRT is also effective for treating a limited number of lung metastases from cancers elsewhere in the body.17PubMed Central. Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Lung Nodules: A Single Institution Series Patients with multiple nodules can receive more than one course of SBRT, though the risk of side effects rises with repeated treatments. Most toxicity from SBRT is mild, but roughly half of patients experience some degree of acute or late side effects, usually low-grade.18PubMed Central. Outcomes of stereotactic body radiotherapy (SBRT) treatment of multiple synchronous and recurrent lung nodules Dose selection matters considerably for achieving lasting local control, and radiation oncologists tailor the treatment plan to the nodule’s size, location, and proximity to critical structures.
Thermal Ablation for Lung Nodules
Image-guided thermal ablation is another minimally invasive option, particularly for patients who are not surgical candidates and for whom radiation may be less suitable. The idea is straightforward: a thin probe is inserted through the chest wall under CT guidance, and the nodule is destroyed using heat. The two main energy sources are radiofrequency ablation and microwave ablation.19PubMed. Radiofrequency and microwave ablation of lung tumors
Microwave ablation has gained ground because it can generate higher temperatures more quickly and is less affected by the heat-sink effect near blood vessels. In one retrospective study, CT-guided percutaneous microwave ablation achieved a local control rate of about 84% for recurrent and metastatic lung tumors.20PubMed Central. CT-guided percutaneous microwave ablation of pulmonary malignant tumors Ablation tends to work best on smaller nodules, and outcomes are generally better when the nodule is peripheral and away from major airways. While it is not a first-line treatment for operable patients, it fills an important gap for those with limited options.
Targeted Therapy and Immunotherapy for Malignant Nodules
When a biopsy reveals that a lung nodule is a primary non-small-cell lung cancer or a metastasis, molecular testing of the tumor tissue can open the door to targeted systemic treatments. Tyrosine kinase inhibitors, for example, are used in cancers driven by specific genetic mutations such as EGFR, ALK, or ROS1 rearrangements. These drugs can shrink tumors dramatically in the right patients. Immune checkpoint inhibitors have further expanded the treatment landscape, improving survival in selected patients with advanced-stage disease.21Signal Transduction and Targeted Therapy. The emerging treatment landscape of targeted therapy in non-small-cell lung cancer
For a single early-stage malignant nodule, systemic therapy alone is rarely the primary approach. Surgery or SBRT is typically preferred for local control. But in cases where there are multiple nodules, where the cancer has spread, or where surgery is not feasible, targeted drugs and immunotherapy form the backbone of treatment. This is why getting adequate tissue for molecular profiling during biopsy is so important; robotic bronchoscopy systems, for instance, yield tissue adequate for next-generation sequencing in over 90% of cases, matching the rates of CT-guided biopsy.7CHEST Pulmonary. CT Scan-Guided Biopsy vs Shape-Sensing Robotic-Assisted Bronchoscopy: Molecular Analysis, Diagnostic Yield, and Clinical Implications
Smoking Cessation and Its Effect on Nodules
If you are a current smoker with lung nodules, quitting is one of the few things within your direct control that has been shown to make a measurable difference. A study of smokers who completed a short-term smoking cessation program found a significant reduction in the size of lung nodules, along with a trend toward fewer nodules overall.22PubMed. Lung nodule and functional changes in smokers after smoking cessation short-term treatment Smoking cessation also improved lung function, which matters if surgery ever becomes necessary, as better baseline lung capacity means lower surgical risk and faster recovery. Quitting will not eliminate every nodule, but it reduces ongoing inflammation that can feed nodule growth and development.
The Psychological Weight of a Lung Nodule
One dimension of living with a lung nodule that rarely makes it into treatment discussions is the emotional toll. Nearly half of people with a newly identified small pulmonary nodule experience some degree of emotional distress within the first couple of months.23Chest. Emotional Distress, Anxiety, and General Health Status in Patients With Newly Identified Small Pulmonary Nodules: Results From the Watch the Spot Trial A broader review found that anxiety affected anywhere from 10% to 42% of patients with pulmonary nodules, with depression reported in roughly 15% to 27%.24PubMed. Pulmonary nodules and the psychological harm they can cause: A scoping review The distress is not trivial: it has been linked to patients choosing more aggressive treatment than their clinical situation warrants, or paradoxically, avoiding follow-up surveillance entirely.
The evidence shows that timely communication from a clinician makes a real difference. In one study, lack of timely notification about a nodule finding was independently associated with greater distress and anxiety.23Chest. Emotional Distress, Anxiety, and General Health Status in Patients With Newly Identified Small Pulmonary Nodules: Results From the Watch the Spot Trial Providing patients with a simple fact sheet about pulmonary nodules improved self-reported anxiety in over 80% of recipients.25PubMed Central. Effect of a pulmonary nodule fact sheet on patient anxiety and knowledge: a quality improvement initiative If you are dealing with nodule-related worry, asking your doctor for clear information about what the nodule looks like, what the plan is, and what the realistic risk level is can go a long way.
The Overdiagnosis Problem
On the flip side of the anxiety coin is the risk of doing too much. Overdiagnosis, where a benign nodule is misidentified as malignant and subjected to unnecessary procedures, is a real and underappreciated issue. One retrospective study found an overdiagnosis rate of 50% for benign pulmonary nodules, meaning that half of the benign nodules in the study cohort underwent procedures that, in hindsight, were unnecessary. Features that increased the risk of overdiagnosis included non-solid nodule type, pleural retraction on imaging, and larger lesion size.26PubMed Central. Factors associated with overdiagnosis of benign pulmonary nodules as malignancy: a retrospective cohort study
Downstream costs compound the problem. When ordering physicians over-manage nodules relative to guideline recommendations, the financial burden escalates sharply.27PubMed. Downstream Costs Associated with Incidental Pulmonary Nodules Detected on CT This is not just about money; unnecessary biopsies carry their own complication risks, and unnecessary surgery on a benign nodule removes healthy lung tissue for no benefit. Shared decision-making is the antidote. Research shows that most patients prefer some form of biopsy over observation when told their nodule has any meaningful risk of being cancer, and willingness to undergo surgery rises steeply once the estimated malignancy risk exceeds about 70%.28BMJ Open. Shared decision-making in the management of pulmonary nodules: a systematic review of quantitative and qualitative studies Having an honest conversation about estimated risk percentages, using the validated models described above, helps both patients and physicians avoid reflexive action.
Emerging Tools That Could Change the Equation
Two areas of active development could reduce both overdiagnosis and diagnostic delays. The first is artificial intelligence applied to CT imaging. Radiomics, which extracts hundreds of quantitative features from CT images that the human eye cannot perceive, has shown strong performance in distinguishing benign from malignant nodules. One such approach could reduce unnecessary biopsies of benign nodules while maintaining high accuracy for identifying cancer.29Scientific Reports. Radiomics as a non-invasive adjunct to Chest CT in distinguishing benign and malignant lung nodules Novel fusion algorithms combining deep learning with radiomics features have achieved classification accuracies above 93% in research settings.30PubMed Central. A novel fusion algorithm for benign-malignant lung nodule classification on CT images
The second development is blood-based biomarkers. A plasma proteomic classifier tested in the PANOPTIC trial demonstrated a sensitivity of 97% and a negative predictive value of 98% for distinguishing benign from malignant nodules in patients with intermediate-risk findings. If clinicians had used the classifier’s results to guide decisions, the study estimated that 40% fewer procedures would have been performed on benign nodules, while only about 3% of malignant nodules would have been missed.31Chest. Assessment of Plasma Proteomics Biomarker’s Ability to Distinguish Benign From Malignant Lung Nodules: Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) Trial Neither AI-based imaging tools nor blood biomarkers have fully replaced traditional workups yet, but they are increasingly being incorporated into clinical decision-making, and they represent the direction the field is heading. For patients caught in the uncomfortable middle ground of an indeterminate nodule, these tools offer the prospect of faster answers with fewer invasive procedures.